{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:27:20Z","timestamp":1790836040748,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mesangial cells-mediated glomerulonephritis is a frequent cause of end-stage renal disease. Here, we show that celastrol is effective in treating both reversible and irreversible mesangioproliferative glomerulonephritis in rat models, but find that its off-target distributions cause severe systemic toxicity. We thus target celastrol to mesangial cells using albumin nanoparticles. Celastrol-albumin nanoparticles crosses fenestrated endothelium and accumulates in mesangial cells, alleviating proteinuria, inflammation, glomerular hypercellularity, and excessive extracellular matrix deposition in rat anti-Thy1.1 nephritis models. Celastrol-albumin nanoparticles presents lower drug accumulation than free celastrol in off-target organs and tissues, thereby minimizing celastrol-related systemic toxicity. Celastrol-albumin nanoparticles thus represents a promising treatment option for mesangioproliferative glomerulonephritis and similar glomerular diseases.<\/jats:p>","DOI":"10.1038\/s41467-017-00834-8","type":"journal-article","created":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T10:56:33Z","timestamp":1507287393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":195,"title":["Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis"],"prefix":"10.1038","volume":"8","author":[{"given":"Ling","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"834_CR1","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJM199809243391306","volume":"339","author":"DE Hricik","year":"1998","unstructured":"Hricik, D. E., Chung-Park, M. & Sedor, J. R. Glomerulonephritis. N. Engl. J. Med. 339, 888\u2013899 (1998).","journal-title":"N. Engl. J. Med."},{"key":"834_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/ndt\/13.suppl_1.10","volume":"13","author":"WG Couser","year":"1998","unstructured":"Couser, W. G. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol. Dial. Transplant. 13, 10\u201315 (1998).","journal-title":"Nephrol. Dial. Transplant."},{"key":"834_CR3","first-page":"1","volume":"65","author":"M Heron","year":"2016","unstructured":"Heron, M. Deaths: leading causes for 2013. Natl Vital. Stat. Rep. 65, 1\u201314 (2016).","journal-title":"Natl Vital. Stat. Rep."},{"key":"834_CR4","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.2169\/internalmedicine.49.3704","volume":"49","author":"Y-Z Chen","year":"2010","unstructured":"Chen, Y.-Z. et al. Meta-analysis of Tripterygium wilfordii Hook F. in the immunosuppressive treatment of IgA nephropathy. Intern. Med. 49, 2049\u20132055 (2010).","journal-title":"Intern. Med."},{"key":"834_CR5","first-page":"380","volume":"13","author":"W Fan","year":"2013","unstructured":"Fan, W. & Wang, X. The progress in the application of Tripterygium wilfordii preparations in kidney disease. J. Clin. Nephrol. 13, 380\u2013381 (2013).","journal-title":"J. Clin. Nephrol."},{"key":"834_CR6","first-page":"246","volume":"12","author":"L Li","year":"2003","unstructured":"Li, L. & Liu, Z. The application of Tripterygium wilfordii in the treatment of glomerulonephritis for twenty five years. J. Nephrol. Dial. Transplant. 12, 246\u2013247 (2003).","journal-title":"J. Nephrol. Dial. Transplant."},{"key":"834_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s11655-013-1380-3","volume":"20","author":"L Li","year":"1981","unstructured":"Li, L., Zhang, X. & Yang, G. Clinical study of Tripterygium wilfordii hook in treating glomerulonephritis. Chin. J. Intern. Med. 20, 216\u2013216 (1981).","journal-title":"Chin. J. Intern. Med."},{"key":"834_CR8","first-page":"409","volume":"7","author":"S Rong","year":"1998","unstructured":"Rong, S., Hu, W., Liu, Z., Tang, Z. & Li, L. A new regime of tripterygium wilfordii hook f. in treating primary mesangial proliferative glomerulonephritis. J. Nephrol. Dial. Transplant. 7, 409\u2013414 (1998).","journal-title":"J. Nephrol. Dial. Transplant."},{"key":"834_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2010.10.025","volume":"303","author":"R Kannaiyan","year":"2011","unstructured":"Kannaiyan, R., Shanmugam, M. K. & Sethi, G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 303, 9\u201320 (2011).","journal-title":"Cancer Lett."},{"key":"834_CR10","first-page":"197","volume":"33","author":"Y He","year":"2013","unstructured":"He, Y., Shi, S., Zhang, R., Qian, J. & Fan, Y. Determination of main effective components inTripterygium glycosides. Chin. J. Pharm. Anal. 33, 197\u2013200 (2013).","journal-title":"Chin. J. Pharm. Anal."},{"key":"834_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jpba.2015.08.043","volume":"117","author":"H Luo","year":"2016","unstructured":"Luo, H. et al. Simultaneous determination of triptolide, tripterifordin, celastrol and nine sesquiterpene alkaloids in Tripterygium preparations using high-performance liquid chromatography-triple quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 117, 195\u2013204 (2016).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"834_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1440-1827.2005.01781.x","volume":"55","author":"N Sakai","year":"2005","unstructured":"Sakai, N. et al. Uninephrectomy induces progressive glomerulosclerosis and apoptosis in anti-Thy1 glomerulonephritis. Pathol. Int. 55, 19\u201326 (2005).","journal-title":"Pathol. Int."},{"key":"834_CR13","doi-asserted-by":"publisher","first-page":"F359","DOI":"10.1152\/ajprenal.00442.2004","volume":"289","author":"S Kr\u00e4mer","year":"2005","unstructured":"Kr\u00e4mer, S. et al. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril. Am. J. Physiol. Renal Physiol. 289, F359\u2013F368 (2005).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"834_CR14","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.V9112055","volume":"9","author":"R Ziswiler","year":"1998","unstructured":"Ziswiler, R., Steinmann-Niggli, K., Kappeler, A., Daniel, C. & Marti, H.-P. Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J. Am. Soc. Nephrol. 9, 2055\u20132066 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"834_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/01480545.2010.494664","volume":"34","author":"S Wang","year":"2011","unstructured":"Wang, S., Liu, K., Wang, X., He, Q. & Chen, X. Toxic effects of celastrol on embryonic development of zebrafish (Danio rerio). Drug Chem. Toxicol. 34, 61\u201365 (2011).","journal-title":"Drug Chem. Toxicol."},{"key":"834_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/CAD.0b013e3283514b68","volume":"23","author":"Y Huang","year":"2012","unstructured":"Huang, Y. et al. Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol. Anticancer Drugs 23, 515\u2013524 (2012).","journal-title":"Anticancer Drugs"},{"key":"834_CR17","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.yexcr.2012.02.025","volume":"318","author":"HE Abboud","year":"2012","unstructured":"Abboud, H. E. Mesangial cell biology. Exp. Cell Res. 318, 979\u2013985 (2012).","journal-title":"Exp. Cell Res."},{"key":"834_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"ME Davis","year":"2008","unstructured":"Davis, M. E. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771\u2013782 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"834_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1021\/bc0501146","volume":"16","author":"SR Popielarski","year":"2005","unstructured":"Popielarski, S. R., Hu-Lieskovan, S., French, S. W., Triche, T. J. & Davis, M. E. A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjugate Chem 16, 1071\u20131080 (2005).","journal-title":"Bioconjugate Chem"},{"key":"834_CR20","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1073\/pnas.1103573108","volume":"108","author":"CHJ Choi","year":"2011","unstructured":"Choi, C. H. J., Zuckerman, J. E., Webster, P. & Davis, M. E. Targeting kidney mesangium by nanoparticles of defined size. Proc. Natl Acad. Sci 108, 6656\u20136661 (2011).","journal-title":"Proc. Natl Acad. Sci"},{"key":"834_CR21","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/S0002-9440(10)63561-4","volume":"163","author":"AWM Minto","year":"2003","unstructured":"Minto, A. W. M., Erwig, L.-P. & Rees, A. J. Heterogeneity of macrophage activation in anti-Thy-1.1 nephritis. Am. J. Pathol. 163, 2033\u20132041 (2003).","journal-title":"Am. J. Pathol."},{"key":"834_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/path.1711620403","volume":"162","author":"P Hall","year":"1990","unstructured":"Hall, P. et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some, neoplasms. J. Pathol. 162, 285\u2013294 (1990).","journal-title":"J. Pathol."},{"key":"834_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115089","volume":"87","author":"R Johnson","year":"1991","unstructured":"Johnson, R. et al. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. a-smooth muscle actin is a marker of mesangial cell proliferation. J. Clin. Invest. 87, 847 (1991).","journal-title":"J. Clin. Invest."},{"key":"834_CR24","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.addr.2010.08.011","volume":"62","author":"YM Scindia","year":"2010","unstructured":"Scindia, Y. M., Deshmukh, U. S. & Bagavant, H. Mesangial pathology in glomerular disease: targets for therapeutic intervention. Adv. Drug Deliv. Rev. 62, 1337\u20131343 (2010).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"834_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hep.21680","volume":"46","author":"L Bellest","year":"2007","unstructured":"Bellest, L., Eschw\u00e8ge, V., Poupon, R., Chazouill\u00e8res, O. & Robert, A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 46, 528\u2013534 (2007).","journal-title":"Hepatology"},{"key":"834_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/clpt.2012.108","volume":"92","author":"J Senior","year":"2012","unstructured":"Senior, J. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin. Pharmacol. Ther. 92, 332\u2013339 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"834_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12098-007-0118-7","volume":"74","author":"B Thapa","year":"2007","unstructured":"Thapa, B. & Walia, A. Liver function tests and their interpretation. Indian J. Pediatr. 74, 663\u2013671 (2007).","journal-title":"Indian J. Pediatr."},{"key":"834_CR28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep.20703","volume":"41","author":"J Polson","year":"2005","unstructured":"Polson, J. & Lee, W. M. AASLD position paper: the management of acute liver failure. Hepatology 41, 1179\u20131197 (2005).","journal-title":"Hepatology"},{"key":"834_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.34.6.597","volume":"34","author":"D Goldberg","year":"1972","unstructured":"Goldberg, D. & Winfield, D. Diagnostic accuracy of serum enzyme assays for myocardial infarction in a general hospital population. Br. Heart J. 34, 597 (1972).","journal-title":"Br. Heart J."},{"key":"834_CR30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/01.CIR.45.2.471","volume":"45","author":"BE Sobel","year":"1972","unstructured":"Sobel, B. E. & Shell, W. E. Serum enzyme determinations in the diagnosis and assessment of myocardial infarction. Circulation 45, 471\u2013482 (1972).","journal-title":"Circulation"},{"key":"834_CR31","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1046\/j.1523-1755.1999.00662.x","volume":"56","author":"A Hartner","year":"1999","unstructured":"Hartner, A., Sch\u00f6cklmann, H., Pr\u00f6ls, F., M\u00fcller, U. & Sterzel, R. B. a8-integrin in glomerular mesangial cells and in experimental glomerulonephritis. Kidney Int. 56, 1468\u20131480 (1999).","journal-title":"Kidney Int."},{"key":"834_CR32","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1681\/ASN.V371342","volume":"3","author":"J-D Sraer","year":"1993","unstructured":"Sraer, J.-D., Adida, C., Peraldi, M., Rondeau, E. & Kanfer, A. Species-specific properties of the glomerular mesangium. J. Am. Soc. Nephrol. 3, 1342\u20131350 (1993).","journal-title":"J. Am. Soc. Nephrol."},{"key":"834_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1042\/bj20031253","volume":"377","author":"J Rejman","year":"2004","unstructured":"Rejman, J., Oberle, V., Zuhorn, I. S. & Hoekstra, D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem. J. 377, 159\u2013169 (2004).","journal-title":"Biochem. J."},{"key":"834_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.nantod.2011.02.003","volume":"6","author":"T-G Iversen","year":"2011","unstructured":"Iversen, T.-G., Skotland, T. & Sandvig, K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 6, 176\u2013185 (2011).","journal-title":"Nano Today"},{"key":"834_CR35","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.4049\/jimmunol.150.3.1074","volume":"150","author":"K Kawasaki","year":"1993","unstructured":"Kawasaki, K. et al. Antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 prevent glomerular injury in rat experimental crescentic glomerulonephritis. J. Immunol. 150, 1074\u20131083 (1993).","journal-title":"J. Immunol."},{"key":"834_CR36","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/ki.1997.108","volume":"51","author":"U Wenzel","year":"1997","unstructured":"Wenzel, U. et al. Monocyte chemoattractant protein-1 mediates monocyte\/macrophage influx in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int. 51, 770\u2013776 (1997).","journal-title":"Kidney Int."},{"key":"834_CR37","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.4049\/jimmunol.143.12.3949","volume":"143","author":"Y Horii","year":"1989","unstructured":"Horii, Y. et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J. Immunol. 143, 3949\u20133955 (1989).","journal-title":"J. Immunol."},{"key":"834_CR38","volume":"151","author":"GH Tesch","year":"1997","unstructured":"Tesch, G. H., Lan, H. Y., Atkins, R. C. & Nikolic-Paterson, D. J. Role of interleukin-1 in mesangial cell proliferation and matrix deposition in experimental mesangioproliferative nephritis. Am. J. Pathol. 151, 141 (1997).","journal-title":"Am. J. Pathol."},{"key":"834_CR39","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1046\/j.1523-1755.1999.07119.x","volume":"56","author":"ZA Massy","year":"1999","unstructured":"Massy, Z. A. et al. The central role of nuclear factor-kappa B in mesangial cell activation. Kidney Int. 56, S76\u2013S79 (1999).","journal-title":"Kidney Int."},{"key":"834_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0272-6386(12)80971-1","volume":"23","author":"WG Couser","year":"1994","unstructured":"Couser, W. G. & Johnson, R. J. Mechanisms of progressive renal disease in glomerulonephritis. Am. J. Kidney Dis. 23, 193\u2013198 (1994).","journal-title":"Am. J. Kidney Dis."},{"key":"834_CR41","doi-asserted-by":"crossref","first-page":"F674","DOI":"10.1152\/ajprenal.1988.255.4.F674","volume":"255","author":"PJ Shultz","year":"1988","unstructured":"Shultz, P. J., DiCorleto, P. E., Silver, B. J. & Abboud, H. E. Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am. J. Physiol. Renal Physiol. 255, F674\u2013F684 (1988).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"834_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bcp.2007.03.015","volume":"74","author":"Y-C Chen","year":"2007","unstructured":"Chen, Y.-C. et al. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways. Biochem. Pharmacol. 74, 10\u201319 (2007).","journal-title":"Biochem. Pharmacol."},{"key":"834_CR43","first-page":"S59","volume":"49","author":"WA Border","year":"1995","unstructured":"Border, W. A., Noble, N. A. & Ketteler, M. TGF-beta: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention. Kidney Int. Suppl. 49, S59\u2013S61 (1995).","journal-title":"Kidney Int. Suppl."},{"key":"834_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jconrel.2012.02.011","volume":"161","author":"K Poelstra","year":"2012","unstructured":"Poelstra, K., Prakash, J. & Beljaars, L. Drug targeting to the diseased liver. J. Control. Release 161, 188\u2013197 (2012).","journal-title":"J. Control. Release"},{"key":"834_CR45","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jhep.2011.05.039","volume":"55","author":"LH Reddy","year":"2011","unstructured":"Reddy, L. H. & Couvreur, P. Nanotechnology for therapy and imaging of liver diseases. J. Hepatol. 55, 1461\u20131466 (2011).","journal-title":"J. Hepatol."},{"key":"834_CR46","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.nano.2016.01.013","volume":"12","author":"J-K Park","year":"2016","unstructured":"Park, J.-K. et al. Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomedicine 12, 1365\u20131374 (2016).","journal-title":"Nanomedicine"},{"key":"834_CR47","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1345\/aph.1Q122","volume":"45","author":"JL Rosselli","year":"2011","unstructured":"Rosselli, J. L., Thacker, S. M., Karpinski, J. P. & Petkewicz, K. A. Treatment of IgA nephropathy: an update. Ann. Pharmacother. 45, 1284\u20131296 (2011).","journal-title":"Ann. Pharmacother."},{"key":"834_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ddmod.2010.08.002","volume":"7","author":"H-C Yang","year":"2010","unstructured":"Yang, H.-C., Zuo, Y. & Fogo, A. B. Models of chronic kidney disease. Drug. Discov. Today Dis. Models 7, 13\u201319 (2010).","journal-title":"Drug. Discov. Today Dis. Models"},{"key":"834_CR49","first-page":"175","volume":"33","author":"L Yuan","year":"2013","unstructured":"Yuan, L., Chen, Y., Zhou, L., Zheng, L. & Cao, W. Determination of protein binding rates of celastrol in different species of plasma by HPLC. Chin. J. Hosp. Pharm 33, 175\u2013179 (2013).","journal-title":"Chin. J. Hosp. Pharm"},{"key":"834_CR50","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1681\/ASN.2009030295","volume":"21","author":"H Shimizu","year":"2010","unstructured":"Shimizu, H. et al. siRNA-based therapy ameliorates glomerulonephritis. J. Am. Soc. Nephrol. 21, 622\u2013633 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"834_CR51","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1053\/j.ackd.2013.06.003","volume":"20","author":"JE Zuckerman","year":"2013","unstructured":"Zuckerman, J. E. & Davis, M. E. Targeting therapeutics to the glomerulus with nanoparticles. Adv. Chronic. Kidney Dis. 20, 500\u2013507 (2013).","journal-title":"Adv. Chronic. Kidney Dis."},{"key":"834_CR52","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.V210s74","volume":"2","author":"GF Schreiner","year":"1992","unstructured":"Schreiner, G. F. The mesangial phagocyte and its regulation of contractile cell biology. J. Am. Soc. Nephrol. 2, S74 (1992).","journal-title":"J. Am. Soc. Nephrol."},{"key":"834_CR53","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1006\/bbrc.1996.0804","volume":"222","author":"M Tamura","year":"1996","unstructured":"Tamura, M. et al. Enhanced glomerular profilin gene and protein expression in experimental mesangial proliferative glomerulonephritis. Biochem. Biophys. Res. Commun. 222, 683\u2013687 (1996).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"834_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1046\/j.1365-2249.2002.01793.x","volume":"128","author":"A Kitching","year":"2002","unstructured":"Kitching, A. et al. Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis. Clin. Exp. Immunol. 128, 36\u201343 (2002).","journal-title":"Clin. Exp. Immunol."},{"key":"834_CR55","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1046\/j.1523-1755.1999.00636.x","volume":"56","author":"Y-M Chen","year":"1999","unstructured":"Chen, Y.-M. et al. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int. 56, 932\u2013943 (1999).","journal-title":"Kidney Int."},{"key":"834_CR56","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/ki.1993.55","volume":"43","author":"J Floege","year":"1993","unstructured":"Floege, J., Eng, E., Young, B. A., Couser, W. G. & Johnson, R. J. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int. 43, 369\u2013380 (1993).","journal-title":"Kidney Int."},{"key":"834_CR57","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1021\/mp500282g","volume":"11","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. Mechanistic studies of a novel mycophenolic acid-glucosamine conjugate that attenuates renal ischemia\/reperfusion injury in rat. Mol. Pharm. 11, 3503\u20133514 (2014).","journal-title":"Mol. Pharm."},{"key":"834_CR58","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1021\/acs.molpharmaceut.5b00536","volume":"12","author":"X Yi","year":"2015","unstructured":"Yi, X. et al. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers. Mol. Pharm. 12, 4085\u20134098 (2015).","journal-title":"Mol. Pharm."},{"key":"834_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135648","volume":"10","author":"H Wang","year":"2015","unstructured":"Wang, H. et al. The Accumulation of VEGFA in the glomerular basement membrane and its relationship with podocyte injury and proteinuria in alport syndrome. PLoS ONE 10, e0135648 (2015).","journal-title":"PLoS ONE"},{"key":"834_CR60","volume":"134","author":"E Ishimura","year":"1989","unstructured":"Ishimura, E., Sterzel, R. B., Budde, K. & Kashgarian, M. Formation of extracellular matrix by cultured rat mesangial cells. Am. J. Pathol. 134, 843 (1989).","journal-title":"Am. J. Pathol."},{"key":"834_CR61","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"834_CR62","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S41775","volume":"8","author":"T Zhang","year":"2013","unstructured":"Zhang, T. et al. A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. Int. J. Nanomed. 8, 1185 (2013).","journal-title":"Int. J. Nanomed."},{"key":"834_CR63","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1021\/mp500637b","volume":"12","author":"X Cao","year":"2014","unstructured":"Cao, X. et al. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo. Mol. Pharm. 12, 274\u2013286 (2014).","journal-title":"Mol. Pharm."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00834-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00834-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00834-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T21:11:31Z","timestamp":1693084291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00834-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["834"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-00834-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]},"assertion":[{"value":"13 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"878"}}